Bindu Anand Balani, MD: Eradicating Hepatitis C Virus by 2030

July 28, 2022
Kenny Walter

Kenny Walter is an editor with HCPLive. Prior to joining MJH Life Sciences in 2019, he worked as a digital reporter covering nanotechnology, life sciences, material science and more with R&D Magazine. He graduated with a degree in journalism from Temple University in 2008 and began his career as a local reporter for a chain of weekly newspapers based on the Jersey shore. When not working, he enjoys going to the beach and enjoying the shore in the summer and watching North Carolina Tar Heel basketball in the winter.

There are several early phase trials underway for new hepatitis B virus treatments.

The advancements in care for hepatitis C virus (HCV) in the last 5-10 years has made it realistic that the disease could be eradicated by 2030, a goal that once seemed unattainable for many in the field.

The major milestone that spurred this moment came in recent years with approvals of direct-acting antivirals (DAA), a relatively new class of drugs that have transformed HCV care.

With DAAs in hand, many patients with HCV are cleared from the disease relatively quickly.

However, it must be a true global push to really achieve the goal of eradicating the disease in the next 8 years.

In this episode of DocTalk, Bindu Anand Balani, MD, Hackensack Meridian Health discusses the momentous movement toward eradication in recent years and whether or not this is a realistic goal worldwide.

One important thing that must happen in order to achieve this goal is to really enhance screenings, particularly following the COVID-19 pandemic. Balani said screenings and catching the virus early, with the addition of DAA treatment, can go a long way toward eradication.

She also said with much of the attention focusing off of HCV, it is an exciting time for hepatitis B virus research, with several drugs in the pipeline in early phase trials that could make an impact in the coming years.


x